SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

Abituzumab

Cat. No.: HY-P99183

CAS No.: 1105038-73-0

Target: Integrin

Pathway: Cytoskeleton

Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description

Abituzumab (DI17E6) is a humanised anti-integrin αV monoclonal antibody (IgG2 type). Abituzumab effectively reduces the phosphorylation of FAK, Akt and ERK. Abituzumab can be used in cancer research, particularly in prostate cancer[1].

IC_{50} & Target

Integrin αV[1].

In Vitro

Abituzumab (DI17E6) (0.01, 0.1, 1, 10, 30,100 μg/mL; 24 h) inhibits adhesion of PCa cells to multiple extracellular matrix proteins but not collagen I[1]

Abituzumab (100 μg/mL; 12, 18 h) inhibits inhibits motility and invasion of PCa cells[1].

Abituzumab (0.01, 0.1, 1, 10, 30,100 μg/mL; 24 h) inhibits the ability of PCa cells to adhere to osteoblast and bone stromal cell lines[1].

Abituzumab (100 μg/mL; 24 h) blocks integrin-mediated cell signaling in PCa cancer cell lines[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line:	PCa cells
Concentration:	0.01, 0.1, 1, 10, 30,100 μg/mL
Incubation Time:	24 h
Result:	Promoted detachment of PCa cells from vitronectin (up to approximately 20% cells detached at 100 μg/mL), osteopontin (up to approximately 10% cells detached at 100 μg/mL) and fibronectin (up to approximately 10% cells detached at 100 μg/mL) but not from collagen I.

Cell Invasion Assay[1]

Cell Line:	PCa cells
Concentration:	100 μg/mL
Incubation Time:	12, 18 h
Result:	Inhibited invasive ability by approximately 25 to 30% compared to vehicle, and inhibited motility by approximately 30 to 40%.

Cell Viability Assay[1]

Cell Line:	PCa, hFOB, Saos2, HS-5, HDMEC cells
Concentration:	0.01, 0.1, 1, 10, 30,100 μg/mL
Incubation Time:	24 h
Result:	Inhibited PCa cells adhesion to human osteoblast cell lines hFOB and Saos2 and a bone marrow stromal cell line, HS-5. Promoted detachment of PCa cells from to a known expressor of αv integrins, HDMEC cells.

Western Blot Analysis[1]

Cell Line:	PC3, DU145, C4-2B, LNCaP, ARCaP and VCaP cells
Concentration:	100 μg/mL
Incubation Time:	24 h
Result:	Inhibited FAK phosphorylation starting at 12 h and 6 h in C4-2B and LNCaP, respectively; AKT phosphorylation starting at 3 h and 2 h in C4-2B and LNCaP, respectively; and ERK phosphorylation at starting at 1 h and 1.5 h in C4-2B and LNCaP, respectively.

REFERENCES

[1]. Jiang Y, et al. Abituzumab Targeting of αV-Class Integrins Inhibits Prostate Cancer Progression. Mol Cancer Res. 2017 Jul;15(7):875-883.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA